Trials / Terminated
TerminatedNCT05518110
PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
PaTcH Trial: A Phase 2 Study to Explore Primary and Emerging Resistance Mechanisms in Patients With Metastatic Refractory Pancreatic Cancer Treated With Trametinib and Hydroxychloroquine
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Cancer Trials Ireland · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to investigate the means by which cancer resists treatment can be overcome by a combination of an established anticancer drug, trametinib, with hydroxychloroquine.
Detailed description
The study is a multi-centre single arm Phase 2 clinical trial to explore primary and emerging resistance mechanisms in patients with metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine. This study will include 10-22 patients with metastatic pancreatic cancer who have previously progressed on at least one line of systemic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trametinib | 2mg of Trametinib (orally) daily. |
| DRUG | Hydroxychloroquine | 1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily. |
Timeline
- Start date
- 2023-05-31
- Primary completion
- 2026-03-03
- Completion
- 2026-03-03
- First posted
- 2022-08-26
- Last updated
- 2026-04-13
Locations
2 sites across 1 country: Ireland
Source: ClinicalTrials.gov record NCT05518110. Inclusion in this directory is not an endorsement.